Dataset
Evaluation of co-therapy with melatonin and methylprednisolone in Experimental Autoimmune Encephalomyelitis (EAE) [Dataset]
Título alternativo | Evaluación de la co-terapia con melatonina y metilprednisolona en la Encefalomielitis Autoinmune Experimental (EAE) [Dataset] |
Autor/es | Álvarez López, Ana Isabel
Álvarez Sánchez, Nuria Cruz Chamorro, Iván Santos Sánchez, Guillermo Ponce España, Eduardo Bejarano, Ignacio Lardone, Patricia Judith Carrillo Vico, Antonio |
Compilador de datos | Álvarez López, Ana Isabel |
Gestor de datos | Álvarez López, Ana Isabel |
Contacto | Carrillo Vico, Antonio |
Departamento | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología |
Idioma (ISO) | inglés (eng) |
Fecha de difusión | 2024-08-01 |
Fecha de depósito | 2024-08-02 |
Fecha de creación | 2022-05 |
Versión | v.1 |
Resumen | The dataset includes the raw data from the clinical score and flow cytometry analyzes carried out in the work titled " Melatonin synergistically potentiates the effect of methylprednisolone on reducing neuroinflammation ... The dataset includes the raw data from the clinical score and flow cytometry analyzes carried out in the work titled " Melatonin synergistically potentiates the effect of methylprednisolone on reducing neuroinflammation in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis". This study shows the protective synergistic effect of co-treatment with melatonin and methylprednisolone on reducing the severity of EAE by decreasing CD4+ lymphocytes, B cells, macrophages and dendritic cells in the CNS, as well as modulating the population of infiltrated T and B cells toward regulatory phenotypes to the detriment of pro-inflammatory effector functions. In addition, treatment with melatonin from the clinical onset of EAE improves the natural course of the EAE and the response to a subsequent treatment with methylprednisolone in a later relapse of the disease. Eight-week-old female C57BL/6N mice were immunized immunization with 100 μg of MOG35–55 (Cambridge Research Biochemicals, Cleveland) emulsified in CFA (Sigma) containing 50 μg of heat-killed Mycobacterium tuberculosis (H37Ra, ATCC 25177) by subcutaneous injection in both hind legs and two doses of intraperitoneal pertussis toxin (200 ng/day) (List Labs, California) on days 0 and 2 post-induction. Animals were randomly divided to receive melatonin at a concentration of 80 mg/kg and/or methylprednisolone at a concentration of 40 or 160 mg/kg in different treatment regimens. Mice were sacrificed at the peak of the disease (day 15 after induction) and after perfusion, the CNS was collected, homogenized and enzymatically dissociated with 1.87 mg/ml of collagenase IV (Worthington) and 0.25 mg/ml of DNase I (AppliChem) for 35 min at 37°C to obtain a suspension of single cells. Subsequently, a 37%:70% discontinous percoll gradient was carried out to isolate CNS-infiltrating mononuclear cells. To assess the profile of infiltrated immune cells in the CNS, cells were stained for the following antibodies against surface markers: CD45, CD4, CD8α, CD19, CD11b, CD11c, CD44, CD62L, B220, CD138, PD-1 (CD279), CTLA-4 (CD152), FAS (CD95), and CD25. To identify Treg and analyze intracellular production of TNF, IFN-γ and IL-10, after surface staining, cells were fixed and permeabilized using the The dataset includes the raw data from the clinical score and flow cytometry analyzes carried out in the work titled " Melatonin synergistically potentiates the effect of methylprednisolone on reducing neuroinflammation in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis". This study shows the protective synergistic effect of co-treatment with melatonin and methylprednisolone on reducing the severity of EAE by decreasing CD4+ lymphocytes, B cells, macrophages and dendritic cells in the CNS, as well as modulating the population of infiltrated T and B cells toward regulatory phenotypes to the detriment of pro-inflammatory effector functions. In addition, treatment with melatonin from the clinical onset of EAE improves the natural course of the EAE and the response to a subsequent treatment with methylprednisolone in a later relapse of the disease. Eight-week-old female C57BL/6N mice were immunized immunization with 100 μg of MOG35–55 (Cambridge Research Biochemicals, Cleveland) emulsified in CFA (Sigma) containing 50 μg of heat-killed Mycobacterium tuberculosis (H37Ra, ATCC 25177) by subcutaneous injection in both hind legs and two doses of intraperitoneal pertussis toxin (200 ng/day) (List Labs, California) on days 0 and 2 post-induction. Animals were randomly divided to receive melatonin at a concentration of 80 mg/kg and/or methylprednisolone at a concentration of 40 or 160 mg/kg in different treatment regimens. Mice were sacrificed at the peak of the disease (day 15 after induction) and after perfusion, the CNS was collected, homogenized and enzymatically dissociated with 1.87 mg/ml of collagenase IV (Worthington) and 0.25 mg/ml of DNase I (AppliChem) for 35 min at 37°C to obtain a suspension of single cells. Subsequently, a 37%:70% discontinous percoll gradient was carried out to isolate CNS-infiltrating mononuclear cells. To assess the profile of infiltrated immune cells in the CNS, cells were stained for the following antibodies against surface markers: CD45, CD4, CD8α, CD19, CD11b, CD11c, CD44, CD62L, B220, CD138, PD-1 (CD279), CTLA-4 (CD152), FAS (CD95), and CD25. To identify Treg and analyze intracellular production of TNF, IFN-γ and IL-10, after surface staining, cells were fixed and permeabilized using the |
Contenido | The data set titled “Mel+MPD co-therapy.xlsx” includes numerical data from flow cytometry analysis (first sheet) and clinical score analysis (second sheet). A legend is also incorporated into the third sheet detailing the ... The data set titled “Mel+MPD co-therapy.xlsx” includes numerical data from flow cytometry analysis (first sheet) and clinical score analysis (second sheet). A legend is also incorporated into the third sheet detailing the different experimental groups of the study. |
Agencias financiadoras | Fundación Progreso y Salud Junta de Andalucía |
Identificador del proyecto | PC-0019- 2017
PI-0015-2018 PI-0485-2014 US-1263804 |
Asociado a la publicación | Ana Isabel Álvarez-López, Nuria Álvarez-Sánchez, Cruz-Chamorro, I., Santos-Sánchez, G., Ponce-España, E., Bejarano, I., Patricia Judith Lardone, & Carrillo-Vico, A. (2024). Melatonin synergistically potentiates the effect of methylprednisolone on reducing neuroinflammation in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Journal of Autoimmunity, 148, 103298–103298. https://doi.org/10.1016/j.jaut.2024.103298 |
Tipo de dataset | Datos numéricos, Bases de datos, Tablas |
Cita | Álvarez López, A.I., Álvarez Sánchez, N.,...,Carrillo Vico, A. (2024). Evaluation of co-therapy with melatonin and methylprednisolone in Experimental Autoimmune Encephalomyelitis (EAE) [Dataset]. idUS (Depósito de Investigación de la Universidad de Sevilla). https://doi.org/10.12795/11441/161856. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Mel+MPD co-therapy.xlsx | 59.03Kb | [Microsoft Excel 2007] | Ver/ | |
Readme_Mel+MPD.txt | 15.87Kb | [Fichero de texto] | Ver/ | |